Business Description
Personalis Inc
NAICS : 325413
SIC : 2835
ISIN : US71535D1063
Total Employee Number:
260Description
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.6 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -0.39 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 10.7 | |||||
Beneish M-Score | -1.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -18.2 | |||||
3-Year EBITDA Growth Rate | 29.7 | |||||
3-Year EPS without NRI Growth Rate | 28.4 | |||||
3-Year FCF Growth Rate | 30.3 | |||||
3-Year Book Growth Rate | -18.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 31.71 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.57 | |||||
9-Day RSI | 64.84 | |||||
14-Day RSI | 64.33 | |||||
3-1 Month Momentum % | 8.2 | |||||
6-1 Month Momentum % | 31.13 | |||||
12-1 Month Momentum % | 148.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.28 | |||||
Quick Ratio | 5.12 | |||||
Cash Ratio | 4.58 | |||||
Days Inventory | 31.86 | |||||
Days Sales Outstanding | 71.94 | |||||
Days Payable | 75.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.9 | |||||
Shareholder Yield % | -1.16 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 12.69 | |||||
Operating Margin % | -164.07 | |||||
Net Margin % | -153.84 | |||||
EBITDA Margin % | -139.55 | |||||
FCF Margin % | -144.94 | |||||
OCF Margin % | -132.48 | |||||
ROE % | -48.13 | |||||
ROA % | -36.38 | |||||
ROIC % | -127.37 | |||||
3-Year ROIIC % | -120.49 | |||||
ROC (Joel Greenblatt) % | -172.21 | |||||
ROCE % | -41.76 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 24 | |||||
PB Ratio | 7.72 | |||||
Price-to-Tangible-Book | 7.72 | |||||
EV-to-EBIT | -15.42 | |||||
EV-to-EBITDA | -16.96 | |||||
EV-to-Revenue | 23.66 | |||||
EV-to-Forward-Revenue | 5.96 | |||||
EV-to-FCF | -16.32 | |||||
Price-to-GF-Value | 6.94 | |||||
| Price-to-Net-Current-Asset-Value | 10.8 | |||||
| Price-to-Net-Cash | 13.34 | |||||
Earnings Yield (Greenblatt) % | -6.49 | |||||
FCF Yield % | -5.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PSNL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Personalis Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 69.669 | ||
| EPS (TTM) ($) | -1.09 | ||
| Beta | 3.3768 | ||
| 3-Year Sharpe Ratio | 0.83 | ||
| 3-Year Sortino Ratio | 2.6 | ||
| Volatility % | 130.49 | ||
| 14-Day RSI | 64.33 | ||
| 14-Day ATR ($) | 0.947962 | ||
| 20-Day SMA ($) | 15.13525 | ||
| 12-1 Month Momentum % | 148.54 | ||
| 52-Week Range ($) | 4.6524 - 18.89 | ||
| Shares Outstanding (Mil) | 106.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Personalis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Personalis Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 17:00 | In 182 days | ||
| Annual report for 2026 | 2027-02-26 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 17:00 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 67 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 13.20 (+6.11%) | ||
| Guidance call for 2026 | 2026-06-03 | 11.14 (+1.09%) | ||
| Craig Hallum 23rd Annual Institutional Investor Conference | 2026-05-28 | 9.49 (+3.60%) | ||
| General meeting for 2026 | 2026-05-12 09:00 | 5.78 (-2.69%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 17:00 | 6.07 (+7.62%) |
Show
Entries
Personalis Inc Frequently Asked Questions
What is Personalis Inc(PSNL)'s stock price today?
The current price of PSNL is $17.07. The 52 week high of PSNL is $18.89 and 52 week low is $4.65.
When is next earnings date of Personalis Inc(PSNL)?
The next earnings date of Personalis Inc(PSNL) is 2026-11-04 Est..
Does Personalis Inc(PSNL) pay dividends? If so, how much?
Personalis Inc(PSNL) does not pay dividend.
Press Release
Articles on Personalis Inc
AMERIPRISE FINANCIAL INC Trims Personalis Inc (PSNL) Stake -- Shares Trade 590% Above GF Value
Aug 21, 2026
Deep Track Capital, LP Trims Personalis Inc (PSNL) Stake -- Shares Trade 590% Above GF Value
Aug 21, 2026
Headlines
See More- 1
Aug 24, 2026
Personalis falls amid a downgrade as a competitive bid appears unlikely
Seeking Alpha • 12:14pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers